456 Studies Now Enrolling
An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
| Sponsor: | Hoffmann-La Roche |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAS5758 |
| U.S. Govt. ID: | NCT03708328 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to determine the doses of RO7121661 that can be administered safely to patients and what the side effects of RO7121661 are. In addition, how RO7121661 affects your body and, in particular, your tumor will be measured. The study also aims to investigate if RO7121661 can slow down or stop the growth of tumors in patients with solid tumors (lung cancer).
This study is closed
Do You Qualify?
| Are you 18 years of age or older? | Yes | No |
| Do you have advanced and/or metastatic solid tumors in your lungs? | Yes | No |
| Have you progressed on a previous cancer therapy, or no effective therapy currently exists for you? | Yes | No |
| Are you willing to come to make extra visits to the doctor and undergo extra tests and procedures? | Yes | No |